Key Takeaway
After 9 months on Wegovy, most patients lose 25 to 40 pounds approaching peak weight loss. Here is a detailed timeline with STEP trial data and guidance.
Nine months on Wegovy means you have been at the full 2.4 mg dose for about four months, and the cumulative results are impressive. Patients researching Wegovy results after 9 months can expect a total weight loss of 25 to 40 pounds, representing approximately 11% to 15% of their starting body weight . You're now approaching the point where weight loss begins to stabilize, though improvements in metabolic health continue.
Nine-Month Results
| Metric | Typical Result at 9 Months |
|---|---|
| Total weight loss | 25 to 40 pounds |
| Body weight percentage | 11% to 15% |
| Waist circumference | 4 to 7 inches lost |
| Blood pressure | 8 to 16 mmHg systolic decrease |
| A1C improvement | 1% to 2% decrease (if improved at baseline) |
| Weight loss rate | Decelerating (1 to 3 lbs per month) |
The STEP 1 trial[1] showed 13.5% weight loss at week 36 for the semaglutide group, increasing to 14.9% at week 68 . The relatively small gap between weeks 36 and 68 illustrates how weight loss decelerates in the later months of treatment.
What Months 7 Through 9 Look Like on Wegovy
After the rapid weight loss of months 4 through 6, the pace settles into a new rhythm:
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
- Monthly weight loss: 2 to 4 pounds per month, down from 4 to 7 during peak months.
- Appetite: Stable and well-controlled. Eating feels natural and effortless at this point.
- Exercise: Your lighter body weight makes physical activity easier and more enjoyable.
- Side effects: Minimal to none at the stable 2.4 mg dose.
- Health markers: Blood pressure, glucose, and lipids remain at improved levels.
The Cardiovascular Benefit
The SELECT trial[2] demonstrated that semaglutide reduces major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in overweight patients with established heart disease . At nine months, your improved blood pressure, lipid profile, inflammation markers, and blood sugar all contribute to substantially lower cardiovascular risk. For a complete cost breakdown, see our compare semaglutide prices.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →This benefit exists independent of weight loss, meaning semaglutide provides cardiovascular protection through mechanisms beyond just reducing body weight .
Managing Expectations at Nine Months
- Weight loss is slowing, and that's okay. You have already achieved the bulk of your total weight loss. Maintaining those results is the next priority.
- Focus on body composition. Even if the scale barely moves, muscle-building and fat loss can continue simultaneously.
- Health improvements continue to accumulate. Cardiovascular, metabolic, and liver benefits deepen even after weight loss stabilizes.
- Celebrate what you have achieved. Losing 25 to 40 pounds is a significant health accomplishment.
Long-Term Planning
- Discuss treatment duration. Will you continue for a full year? Longer? Your provider will help assess.
- Explore dose improvement. Some patients maintain their weight at 1.7 mg, reducing cost.
- thorough health assessment. Full lab panel, body composition, and cardiovascular fitness testing.
- Build sustainable habits. The skills and patterns you have developed during treatment are your foundation for long-term success FormBlends telehealth consultation.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
Frequently Asked Questions
Should I continue Wegovy past 9 months?
Most patients benefit from continuing for at least 12 months. Some continue indefinitely for weight maintenance. Stopping typically leads to weight regain .
Can I switch to compounded semaglutide to save money?
Yes. Compounded semaglutide uses compounded formulations of the active ingredient at a lower cost. Your provider can transition you smoothly FormBlends pricing.
Is the weight loss plateau permanent?
The deceleration at months 8 to 10 is normal. Some patients see a slight rebound in weight loss rate with exercise changes or dietary adjustments. Others stabilize at their new weight. Both outcomes are healthy.
What if I want to lose more weight?
If you're at 2.4 mg and want additional weight loss, options include intensifying exercise, improving nutrition, or potentially switching to tirzepatide, which produces greater total weight loss Wegovy vs Zepbound comparison.
How do I prevent weight regain after stopping Wegovy?
The most effective strategies include maintaining exercise habits, following a protein-rich diet, monitoring your weight weekly, and considering a lower maintenance dose rather than stopping entirely .
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →